Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleISS is asking a federal court to block Oklahoma's Proxy Advisor Transparency Act before it takes effect November 1. The law requires written financial analysis for any recommendation against management, and the same model has already failed in three states.
An appeals court has ruled that private citizens who sue fraudsters on the government's behalf are not constitutional officers, reversing the ruling that threatened the False Claims Act's enforcement machine. The bigger fight is now headed toward the Supreme Court.
The European Commission wants clinical trial authorization cut from about 106 days to 75. The EU's first progress report on its 2030 trial targets shows why the Act exists: the continent's trial machine is running behind its own goals.
An Australian Federal Court has found comparison site Choosi misled customers by claiming to survey a range of insurers while overwhelmingly comparing policies from one. The ruling draws a legal line around the word range.
California's pending SB 903 would ban unlicensed AI therapy and restrict how licensed professionals use AI with patients. The bill's principle is that what matters is the conduct, not what the app calls itself.
From October 1 Australian businesses cannot add card surcharges, and the Reserve Bank is cutting interchange fees to pay for it. The cost is moving, not disappearing, and the first bill has landed on rewards cards.
Australia's My Feed, My Way bill would force social platforms to offer users a real choice over algorithmic feeds. The fight is not over the opt-out; it is over which feed the platform is allowed to make the default.
Judge Leonie Brinkema refused to break up Google's advertising technology and instead imposed conduct remedies, a choice rooted in one uncomfortable finding: the market moved faster than the case.
The Supreme Court will hear consolidated challenges to assault-weapons bans in Illinois and Connecticut on December 2, and the Solicitor General has filed on the challengers' side. The argument will turn on what "common use" means.
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Generative AI should have commoditized this category, and instead Forrester's criteria count kept climbing, because the moat was always licensed source access, not summarization.
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleWith James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the ArticleEvery article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceRates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgageBudgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceContracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealth coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareGartner and Forrester categories for B2B, translated into plain-English analysis for buyers, not analyst-subscription holders.
Browse ResearchWe start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Mavengity is reader-supported and editorially independent from the products we cover.